Literature DB >> 16441547

Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions.

Tiina Pääkkönen1, Tiina M Mäkinen, Juhani Leppäluoto, Olli Vakkuri, Hannu Rintamäki, Lawrence A Palinkas, Juhani Hassi.   

Abstract

The aim of this study was to examine whether urinary melatonin, rather than urinary 6-sulfatoxymelatonin (aMT6s), can be used as an indicator of diurnally and seasonally changing melatonin secretion. The subjects (n=15) spent three separate 24-hr periods in a climatic chamber during winter (n=7) and summer (n=8). Blood and urine samples were obtained during each period at 2- to 5-hr intervals. Serum melatonin and urinary melatonin and aMT6s were assayed by radioimmunoassay. The serum melatonin levels increased nearly 10-fold from low daytime to high nocturnal values. The mean nocturnal increase of urinary melatonin was 1.7-fold and that of urinary aMT6s was 4.6-fold. Both urinary melatonin and aMT6s correlated significantly with area under the curve melatonin in serum during the night, during the day and throughout the entire 24-hr observation period in all cases. The ratio between urinary melatonin and aMT6s excretion showed significant diurnal variation, being ninefold higher at 16:00 hr than at 07:00 or at 09:00 hr. The ninefold decrease in the urinary melatonin/aMT6s excretion ratio between the evening and the morning may reflect increased liver metabolism of melatonin during the night. Both urinary melatonin and aMT6s are good indicators of melatonin secretion, but the variation is significantly smaller for the former molecule.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441547     DOI: 10.1111/j.1600-079X.2005.00300.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  16 in total

1.  Urine citrate and 6-sulfatoximelatonin excretion during a training season in top kayakers.

Authors:  Paula Nuñez; Elena Diaz; Nicolas Terrados; Beatriz Diaz
Journal:  Eur J Appl Physiol       Date:  2012-03-31       Impact factor: 3.078

2.  Pharmacokinetics of melatonin in preterm infants.

Authors:  Nazakat M Merchant; Denis V Azzopardi; Ahmed F Hawwa; James C McElnay; Benita Middleton; J Arendt; Tomoki Arichi; Pierre Gressens; A David Edwards
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

3.  Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes.

Authors:  Wei Chen; Hui Cao; Qian-Yi Lu; Na Wang; Shu-Zhi Zhao; Xun Xu; Zhi Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors.

Authors:  Marta Imbesi; Tolga Uz; Svetlana Dzitoyeva; Pietro Giusti; Hari Manev
Journal:  Brain Res       Date:  2008-06-28       Impact factor: 3.252

5.  Urinary 6-sulphatoxymelatonin levels in patients with senile cataracts.

Authors:  Muberra Akdogan; Yasemin U Budak; Kagan Huysal
Journal:  BMC Ophthalmol       Date:  2013-09-22       Impact factor: 2.209

6.  Metabolic Impact of Light Phase-Restricted Fructose Consumption Is Linked to Changes in Hypothalamic AMPK Phosphorylation and Melatonin Production in Rats.

Authors:  Juliana de Almeida Faria; Thiago Matos F de Araújo; Daniela S Razolli; Letícia Martins Ignácio-Souza; Dailson Nogueira Souza; Silvana Bordin; Gabriel Forato Anhê
Journal:  Nutrients       Date:  2017-03-27       Impact factor: 5.717

7.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

8.  Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates.

Authors:  Karim Fifel; Julien Vezoli; Kwamivi Dzahini; Bruno Claustrat; Vincent Leviel; Henry Kennedy; Emmanuel Procyk; Ouria Dkhissi-Benyahya; Claude Gronfier; Howard M Cooper
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

9.  Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.

Authors:  Marta Batllori; Marta Molero-Luis; Luisa Arrabal; Javier de Las Heras; Joaquín-Alejandro Fernandez-Ramos; Luis González Gutiérrez-Solana; Salvador Ibáñez-Micó; Rosario Domingo; Jaume Campistol; Aida Ormazabal; Frederic Sedel; Thomas Opladen; Basiliki Zouvelou; Roser Pons; Angels Garcia-Cazorla; Eduardo Lopez-Laso; Rafael Artuch
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

10.  Feasibility and Preliminary Efficacy of a Bright Light Intervention in Ovarian and Endometrial Cancer Survivors.

Authors:  Rina S Fox; Sharon H Baik; Heather McGinty; Sofia F Garcia; Kathryn J Reid; Katrin Bovbjerg; Precilla Fajardo; Lisa M Wu; Shohreh Shahabi; Jason C Ong; Phyllis C Zee; Frank J Penedo
Journal:  Int J Behav Med       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.